Publications & News

Stay Up-To-Date with Prolong

October 20, 2025

Prolong Pharmaceuticals to Present Phase 1/2 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 World Stroke Conference (WSC)

Latest

October 20, 2025

Prolong Pharmaceuticals to Present Phase 1/2 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 World Stroke Conference (WSC)

February 5, 2025

Prolong Pharmaceuticals to Present Preliminary Phase 1 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 International Stroke Conference (ISC)

November 13, 2024

Prolong Pharmaceuticals to Present Clinical Data regarding PP-007, PEGylated carboxyhemoglobin bovine product, at the 2024 International Symposium on Blood Substitutes (ISBS)

October 30, 2024

U.S. Food and Drug Administration (FDA) Grants Prolong Pharmaceuticals FDA Fast Track Designation for Novel Stroke Therapy (PP-007) in HEMERA-1 Clinical Study

All our resources

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

October 1, 2023

Measuring And Controlling Potency Of A Targetless Biologic: Study Of Pegylated Hemoglobin

Prolong Pharmaceuticals Announces Presentation of Phase 1 Data from HEMERA-1 Clinical Study of PP-007 in Patients with Acute Ischemic Stroke at the Late-Breaking Science Session, ISC 2023

February 12, 2023

Pan Arab Interventional Radiology Society Annual Congress (PAIRS): Hemera 1 Carboxyhemoglobin Oxygen Delivery for Revascularization in Acute Stroke: Phase 1 Clinical Trial

February 9, 2023

International Stroke Conference (ISC): Hemera 1 Carboxyhemoglobin Oxygen Delivery for Revascularization in Acute Stroke: Phase 1 Clinical Trial

October 1, 2022

Purification and Heat Inactivation of an Oxidation Prone Protein: Study of Hemoglobin

October 1, 2020

Application of Slope Spectroscopy® to the Measurement of Co-oximetry Parameters in Bovine Hemoglobin: The Case of Measuring Low Concentration Met Hemoglobin in Bovine Hemoglobin Samples

October 1, 2020

Characterization of large conjugate (PEGylated) biologics: Combination approach with CE-SDS and SEC-MALS methods

Targeting the Heme Oxygenase 1/Carbon Monoxide Pathway to Resolve Lung Hyper-Inflammation and Restore a Regulated Immune Response in Cystic Fibrosis.

Targeting the HO-1/CO Pathway with Sanguinate: Toward Development of a Novel Anti-inflammatory Therapy for Cystic Fibrosis (CF) Lung Disease

Learn how you can be part of the journey

Join us in revolutionizing treatments for severe
and life-threatening conditions

or